Research Progress of m6A Demethylase FTO and Its Inhibitors in Acute Myeloid Leukemia --Review.
10.19746/j.cnki.issn.1009-2137.2023.03.042
- Author:
Ze-Hao FANG
1
,
2
;
Su-Ying ZHENG
1
,
2
;
Wei-Ying FENG
3
Author Information
1. School of Medicine, Shaoxing University
2. Shaoxing People's Hospital, Shaoxing 312000, Zhejiang Province, China.
3. Department of Hematology, Shaoxing People's Hospital, Shaoxing 312000, Zhejiang Province, China. E-mail: fengweiying1997@126.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
m6A demethylases;
obesity-associated protein
- MeSH:
Humans;
Methylation;
Leukemia, Myeloid, Acute/genetics*;
Prognosis;
Alpha-Ketoglutarate-Dependent Dioxygenase FTO/metabolism*
- From:
Journal of Experimental Hematology
2023;31(3):902-906
- CountryChina
- Language:Chinese
-
Abstract:
Obesity-associated protein (FTO) is an important m6A demethylase that regulates RNA methylation modification and can promote the proliferation of acute myeloid leukemia(AML) cells. FTO regulates the methylation level of AML through multiple cellular signaling pathways such as FTO/RARA/ASB2, FTO/m6A/CEBPA, and PDGFRB/ERK, and participates in the occurrence, development, treatment and prognosis of AML. At present, studies have found that a variety of inhibitors targeting FTO have shown good anti-leukemia effects, and the study of FTO will provide new ideas for the treatment of AML. This review focus on the mechanism of action of FTO in AML and the research progress of FTO inhibitors in AML.
